^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Q-1802 (PD-L1 inhibitor, CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study
Published date:
05/26/2022
Excerpt:
One Gastric cancer patient (moderate CLDN18.2 expression at baseline) with prior heavily treatment observed clinical benefit and response with Non-CR/Non-PD at first tumor assessment at dose of 10mg/kg and continues the therapy.
DOI:
10.1200/JCO.2022.40.16_suppl.2568
Trial ID:
